CLNN Stock Summary and Trading Ideas (Clene | NASDAQ:CLNN)

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Clene trades on the NASDAQ stock market under the symbol CLNN.

As of July 31, 2026, CLNN stock price declined to $5.01 with 33,319 million shares trading.

CLNN has a beta of 3.23, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.09 to the broad based SPY ETF.

CLNN has a market cap of $64.08 million. This is considered a Micro Cap stock.

Last quarter Clene reported $15,000 in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-20,064 and missed earnings estimates by -$.03.

In the last 3 years, CLNN traded as high as $15.80 and as low as $2.28.

The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF, IWC.

CLNN has outperformed the market in the last year with a return of +43.7%, while the SPY ETF gained +18.9%. However, in the most recent history, CLNN shares have underperformed the stock market with its stock returning -18.6% in the last 3 month period and -11.9% for the last 2 week period, while SPY has returned +4.2% and -0.5%, respectively.

CLNN support price is $4.83 and resistance is $5.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.